Singapore, March 24 -- PharmaMar, a Spanish biopharmaceutical company with 40 years of experience, has announced that its treatment Zepzelca(R) (lurbinectedin), in combination with atezolizumab (Tecentriq(R)), has been approved by the Taiwan Food and Drug Administration (TFDA) as a first-line maintenance treatment for adult patients with advanced small cell lung cancer (SCLC).

This approval as a first-line maintenance therapy means that the drug is administered after the initial induction treatment for those patients who achieve stable disease or better, in order to maintain the response achieved. In addition to Taiwan, this first-line maintenance combination has recently been approved for the same indication in the United Arab Emirates,...